BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301

Reuters01-07

Jan 7 (Reuters) - Cingulate Inc CING.O:

CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD ASSET CTX-1301
CINGULATE INC: NO SERIOUS ADVERSE EVENTS REPORTED
CINGULATE INC: SUBMISSION OF NEW DRUG APPLICATION TARGETED FOR MID 2025

Source text: ID:nGNX95Hjxz

Further company coverage: CING.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501050612?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-07 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501050612","market":"us","top_or_hot":-1,"title":"BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301</title></head><body><p><span>Jan 7 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD ASSET CTX-1301</p></li><li><p>CINGULATE INC: NO SERIOUS ADVERSE EVENTS REPORTED</p></li><li><p>CINGULATE INC: SUBMISSION OF NEW DRUG APPLICATION TARGETED FOR MID 2025</p></li></ul><p>Source text: <span>ID:nGNX95Hjxz</span></p><p>Further company coverage: <span>CING.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-07 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301</title></head><body><p><span>Jan 7 (Reuters)</span><span> - </span>Cingulate Inc <span>CING.O</span>:</p><ul><li><p>CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD ASSET CTX-1301</p></li><li><p>CINGULATE INC: NO SERIOUS ADVERSE EVENTS REPORTED</p></li><li><p>CINGULATE INC: SUBMISSION OF NEW DRUG APPLICATION TARGETED FOR MID 2025</p></li></ul><p>Source text: <span>ID:nGNX95Hjxz</span></p><p>Further company coverage: <span>CING.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CING","symbol_name":"CINGULATE INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O30NU:1","article_id":"2501050612","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501050612","pubTimestamp":1736255022,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301Jan 7 (Reuters) - Cingulate Inc CING.O:CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD ASSET CTX-1301CINGULATE IN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CING":"CINGULATE INC.","BK4007":"制药"},"translate_title":"简介-Cingulate Inc Cingulate主要资产Ctx-1301的最终研究已完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CING":0.9},"content_text":"BRIEF-Cingulate Inc Final Study Completed For Cingulate's Lead Asset Ctx-1301Jan 7 (Reuters) - Cingulate Inc CING.O:CINGULATE INC: FINAL STUDY COMPLETED FOR CINGULATE'S LEAD ASSET CTX-1301CINGULATE INC: NO SERIOUS ADVERSE EVENTS REPORTEDCINGULATE INC: SUBMISSION OF NEW DRUG APPLICATION TARGETED FOR MID 2025Source text: ID:nGNX95HjxzFurther company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501050612"}